Table 2.
Tumor response rates according to mRECIST and RECIST 1.1.
| Response, n (%) | T | TL | TLT | P | T | TL | TLT | P |
|---|---|---|---|---|---|---|---|---|
| mRECIST | RECIST 1.1 | |||||||
| CR | 0 (0) | 4 (8.9) | 11 (16.7) | 0.024 | 0 (0) | 0 (0) | 0 (0) | |
| PR | 12 (31.6) | 20 (44.4) | 42 (63.6) | 5 (13.2) | 13 (28.9) | 30 (45.5) | ||
| SD | 16 (42.1) | 12 (26.7) | 9 (13.6) | 20 (52.6) | 23 (51.1) | 31 (47.0) | ||
| PD | 10 (26.3) | 9 (20.0) | 4 (6.1) | 13 (34.2) | 9 (20.0) | 5 (7.5) | ||
| ORR | 12 (31.6) | 24 (53.3) | 53 (80.3) | <0.001 | 5 (13.2) | 13 (28.9) | 30 (45.5) | 0.003 |
| DCR | 28 (73.7) | 36 (80.0) | 62 (93.9) | 0.014 | 25 (65.8) | 36 (80.0) | 61 (92.5) | 0.003 |
mRECIST, modified Response Evaluation Criteria in Solid Tumors; RECIST 1.1, Response Evaluation Criteria in Solid Tumors 1.1; T, TACE, transarterial chemoembolization; TL, TACE combined with lenvatinib; TLT, TACE combined with lenvatinib and tislelizumab; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate; CI, confidence interval.